NCT04405167View on ClinicalTrials.gov

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

May 19, 2025

Study Completion Date

July 1, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Tasquinimod

Tasquinimod will be supplied as oral capsules.

DRUG

IRd chemotherapy

IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Active Biotech AB
All Listed Sponsors
collaborator

Active Biotech AB

INDUSTRY

lead

University of Pennsylvania

OTHER